Dale JD - Emmaus Life G Counsel
| EMMADelisted Stock | USD 0.26 0.00 0.00% |
Insider
Dale JD is G Counsel of Emmaus Life Sciences
| Phone | 310 214 0065 |
| Web | https://www.emmausmedical.com |
Emmaus Life Management Efficiency
The company has return on total asset (ROA) of (0.1239) % which means that it has lost $0.1239 on every $100 spent on assets. This is way below average. Emmaus Life's management efficiency ratios could be used to measure how well Emmaus Life manages its routine affairs as well as how well it operates its assets and liabilities.Emmaus Life Sciences currently holds 4.65 M in liabilities. Emmaus Life Sciences has a current ratio of 0.14, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Emmaus Life until it has trouble settling it off, either with new capital or with free cash flow. So, Emmaus Life's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Emmaus Life Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Emmaus to invest in growth at high rates of return. When we think about Emmaus Life's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Peter MD | Acrivon Therapeutics, Common | 61 | |
| Jc MD | Adagene | 59 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Guizhong Liu | Adagene | 53 | |
| FAAD MBA | AnaptysBio | 47 | |
| Crystal Mercado | Acrivon Therapeutics, Common | N/A | |
| Erick MD | Acrivon Therapeutics, Common | 66 | |
| Daniel Faga | AnaptysBio | 44 | |
| Kristina Masson | Acrivon Therapeutics, Common | 44 | |
| Rasmus HolmJorgensen | Acrivon Therapeutics, Common | 52 | |
| Qinghai Zhao | Adagene | 63 | |
| Man MBA | Adagene | 47 | |
| Jesper Olsen | Acrivon Therapeutics, Common | N/A | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Fangyong Du | Adagene | 54 | |
| Dennis Mulroy | AnaptysBio | 69 | |
| MSc MBA | AnaptysBio | 48 | |
| Kenneth Cundy | Anebulo Pharmaceuticals | 65 | |
| BSc MA | Cell Source | 73 | |
| Eric Devroe | Acrivon Therapeutics, Common | 45 | |
Management Performance
| Return On Asset | -0.12 |
Emmaus Life Sciences Leadership Team
Elected by the shareholders, the Emmaus Life's board of directors comprises two types of representatives: Emmaus Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Emmaus. The board's role is to monitor Emmaus Life's management team and ensure that shareholders' interests are well served. Emmaus Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Emmaus Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| MS MBA, Consultant | ||
| Steven Lee, Independent Consultant | ||
| Dale JD, G Counsel | ||
| George Sekulich, VP Officer | ||
| PharmD PharmD, Clinical, Affairs | ||
| MD MPH, Chairman CEO | ||
| Willis MS, Vice COO |
Emmaus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Emmaus Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.12 | ||||
| Profit Margin | (1.14) % | ||||
| Operating Margin | (0.65) % | ||||
| Current Valuation | 49.41 M | ||||
| Shares Outstanding | 49.56 M | ||||
| Shares Owned By Insiders | 38.73 % | ||||
| Number Of Shares Shorted | 41.22 K | ||||
| Price To Earning | (1.60) X | ||||
| Price To Sales | 1.06 X | ||||
| Revenue | 20.61 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Emmaus OTC Stock
If you are still planning to invest in Emmaus Life Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Emmaus Life's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |